Research programme: MerTK inhibitors - Rigel Pharmaceuticals

Drug Profile

Research programme: MerTK inhibitors - Rigel Pharmaceuticals

Alternative Names: Mer-Axl

Latest Information Update: 06 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigel Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c-mer inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Jun 2016 Research programme: MerTK inhibitors - Rigel Pharmaceuticals is available for licensing as of 06 Jun 2016.
  • 16 Apr 2016 Preclinical trials in Cancer in USA (unspecified route) before 16 Apr 2016
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Cancers presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top